Ad:AJT book order
Ads:Current issue FRUIT PROCESSINGWorld Of Fruits 2024Our technical book Apple Juice TechnologyFRUIT PROCESSING Online Special: Instability of fruit-based beveragesFRUIT PROCESSING Online Special: Don’t give clogs a chanceOrange Juice ChainOur German magazine FLÜSSIGES OBST

Addition significantly expands ADM’s wide array of innovative, groundbreaking products and solutions to help meet $775 billion global demand in health & wellness

ADM, a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland Probiotics & Enzymes.

“The microbiome represents one of ADM’s six strategic growth platforms, and with global demand for health and wellness products estimated at more than $775 billion, today’s investment represents a significant step forward for ADM,” said ADM Chairman and CEO Juan Luciano. “Deerland Probiotics & Enzymes is a leader in probiotic, prebiotic and enzyme technology, with global sales and manufacturing in the U.S. and Europe, and is a perfect fit for our growing portfolio of functional ingredients and solutions for health-conscious consumers. We expect the addition of the Deerland capabilities and portfolio to deliver synergies for our Health & Wellness business and support growth across our Nutrition business unit.”

Deerland Probiotics & Enzymes is a trusted global provider of probiotic and dietary supplements using probiotic, prebiotic, and enzyme technology, including 12 branded product lines serving customers in areas including digestive health, immune health, women’s health, food intolerance, sports nutrition, cellular repair, and systemic and cardiovascular health. The company’s products and solutions include spore probiotics, which offer enhanced stability for a wider use in food and beverage, pet nutrition and supplement applications. Based in Kennesaw, Georgia, U.S., Deerland operates five manufacturing facilities, one fermentation facility, and eight R&D and quality control laboratories globally.

“The hand-in-glove fit of Deerland’s vast portfolio of branded technologies, clinical studies and world-class dosage form production capabilities combined with ADM’s Health and Wellness solutions is strong and unparalleled, allowing us to provide our dietary supplement, food/beverage and companion animal customers with a much broader array of products and capabilities,” said Scott Ravech, Deerland Probiotics & Enzymes CEO. “The Deerland team could not be more excited at the opportunity to be a part of the ADM family.”
The Deerland acquisition is the latest in a series of ADM strategic investments to build a full-scale global Health & Wellness business to help meet fast-growing demand for food, beverages and supplements that enhance health and wellbeing. Growth initiatives have included acquisitions like Protexin and Biopolis, organic capacity investments to expand probiotics production at our Valencia facility, and our recently-announced joint venture and previous partnership with Vland. With the revenue contribution from the addition of Deerland, annualized revenue for Health & Wellness will exceed $500 million.

The transaction, which is subject to regulatory approval, is expected to be completed in the coming weeks; when that occurs, Deerland’s approximately 320 colleagues will transfer to ADM.

Doctor’s Biome, a probiotic health and wellness shot composed of 15 strains of extensively researched, science-backed probiotics is now available in Canada

Doctor’s Biome, a leader in clinically validated juice-based probiotics, founded by a group of doctors and scientists now offers shipping to Canada. “We are extremely excited to be able to expand into Canada and offer this unique, one of a kind probiotic,” says Dr. Howard Robins, the Co-founder and Chief Medical Officer. “Hundreds of my patients in my ozone-therapy practice have seen a significant change in their gut health. Helping people achieve their health and wellness goals has always been a driving force behind Doctor’s Biome.”

Unlike other probiotic brands in capsule or tablet form on the market, Doctor’s Biome guarantees active, living probiotics in an organic vegetable-fruit juice. Since Doctor’s Biome is in a fully hydrated liquid form, it allows for faster absorption and maximum benefit.

In order for probiotics to be most effective, they should be living at the time of manufacture and also upon entering your digestive system. Doctor’s Biome provides active, living strains of probiotics with each daily dose that remain alive upon entering your digestive tract and then continue to flourish in your gut microbiome.

Doctor’s Biome only uses strains that have been extensively researched. The 15 strains of probiotics or “healthy bacteria” compete against a spectrum of harmful bacteria and yeasts for nutrients and space, which helps to rebalance the gut and support healthy digestion.

About Doctor’s Biome
Doctor’s Biome is a synbiotic, which is a combination of prebiotics (the food that feeds the good bacteria in your gut) and probiotics (good bacteria in your gut that normalizes and rebalances your gut microbiome) that work together in the gut.

  • Prebiotics: fiber in the organic vegetable-fruit juice feeds the probiotics, which in turn help them propagate so that they can outnumber the bad bacteria in your gut and create a healthy GI tract.
  • Probiotics: 15 scientifically-backed strains of probiotics targeted to help normalize digestion and rebalance the amount of good bacteria in your gut microbiome.

The acquisition of PrecisionBiotics Group will advance Novozymes’ activities in the area of biological solutions for human oral and gut health – one of the growth pillars in the strategy Better business with biology.

Novozymes announced that it has acquired PrecisionBiotics Group Limited. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically backed products already in the market.

“This acquisition fits well with our strategy, Better business with biology, where we have focus on human health as one of our opportunities for growth. With this investment, we take another important step in implementing the strategy and setting a foundation of growth for our business,” says Ester Baiget, President and CEO of Novozymes.

Combining the power of probiotics and enzymes

PrecisionBiotics Group has strong expertise within clinical development, upscaling and commercialization and is well situated in Cork, Ireland, home to a leading academic society within human gut health.

“We welcome employees in PrecisionBiotics Group to Novozymes. PrecisionBiotics Group brings in complementary technologies, a similar science-based approach and a matching culture. With our unique expertise within discovery and enzymes and PrecisionBiotics’ strong capabilities and network within probiotics for human health, we will be in a unique position. It’s a position where we can expand market opportunities and develop new and highly efficient products,” says Ester Baiget.

“By becoming a part of Novozymes, we will get a global presence across businesses and new capabilities within science and discovery of new strains. This will help us to grow by developing new products where we can combine enzymes and probiotics,” says Barry Kiely, CEO and co-founder of PrecisionBiotics Group.

When combined, enzymes and probiotics synergistically work hand-in-hand to address health benefits from different angles in more powerful ways.

“Novozymes is a strong company based on science with a global market presence and a purpose to find biological solutions for better lives in a growing world. We look forward to speeding up the development of our pipeline and to a global roll-out of products to accelerate growth,” Barry Kiely says.

Novozymes has established OneHealth to market solutions within human health under one umbrella. The aim is to help people live healthier and better lives by use of probiotics and enzymes.

The acquisition of HSO Health Care GmbH cements Chr. Hansen’s long-term commitment to its probiotics business, and the fast-growing category for women’s health, where scientifically proven probiotic solutions are becoming increasingly popular among consumers.

Chr. Hansen Holding A/S and HSO Health Care GmbH entered into an agreement, under which Chr. Hansen will acquire HSO Health Care. The acquisition of the Austria-based B2B company specializing in probiotics for women’s health will strengthen and expand Chr. Hansen’s global microbial platform. This acquisition is aligned with the strategy of pursuing bolt-on acquisitions that fit into the microbial platform, as outlined in the Nature’s no. 1 strategy. The transaction will be finalized later this week.

A scientific approach to common urogenital discomforts

Urogenital discomfort is a concern for women all over the world who are increasingly looking for intimate care products based on natural ingredients. This has driven the category for women’s health to be among the fastest-growing in the probiotics market.

Highlights

  • Women’s health is one of the fastest growing probiotic segments, with an estimated market CAGR of more than 15 % since 2015, which HSO has outperformed substantially
  • Good fit to Chr. Hansen with easy integration and strong potential synergies
  • Strengthens and expands Chr. Hansen’s microbial platform by adding HSO’s branded portfolio Astarte, a global award-winning line of patented probiotic products for women’s health
  • Clinically documented and using four specific strains, Astarte™ has a powerful selling proposition and a strong brand position and is sold in multiple channels
  • Strengthens our women’s health offering by combining Astarte with Chr. Hansen’s UREX products, creating a portfolio that can be leveraged globally and expanded into new adjacencies within women’s health
  • Expected 2020 revenues of approximately EUR 15 million, with an EBITDA margin above 40 %. Strong double-digit organic growth expected from 2020-2025
  • Chr. Hansen’s outlook for 2019/20 is unchanged

Financial implications and outlook

The acquisition is fully aligned with Chr. Hansen’s capital allocation principles, and does not impact the ability pay out an ordinary dividend of 40 – 60 % of net profit. The purchase price will be financed from existing available cash and bank facilities, and the acquisition has no impact on the 2019/20 outlook. Under the terms of the agreement the details of the transaction will not be disclosed.

The global Probiotics Market value is projected to surpass USD $3.5 billion by 2026, according to a new research report by Global Market Insights, Inc. Changing consumer perception towards easily digestible food and beverages and the rising awareness of the potential benefits of probiotic-enhanced supplements may boost market share.

Increasing probiotics industry demand for high-quality food additives, owing to the changing perception towards overall wellness and rising disposable income, may boost market share. Probiotics-strain-enhanced additives are widely used to improve the nutritional profile of non-dairy, meat, and baked preparations, owing to their rich concentration of antioxidants and vital amino acids, which are likely to encourage market demand. Consumers are shifting towards alternate versions of their favorite snacks, which are fortified by probiotic strains, as they aid in healthy digestion, which may augment market share.

A rising prevalence of poor diets, an increasing elderly population with reduced nutritional uptake capability, and growing health awareness may promote the growth of the probiotics market for food supplement applications. Food supplements offer various advantages, such as offering multiple bacterial strains in a potent dose, correcting bacterial concentrations in the digestive tract, and alleviating abdominal discomfort which should boost market demand.  Moreover, they boost the immune system and prevent bacterial and fungal infections by resisting against airborne pathogens, which is likely to boost market share.

Some major findings of the probiotics market report include:

  • The demand for probiotics is increasing due to their benefits, such as their immune system strengthening nature and for the regulation of insulin and bile
  • Rising market demand for high-quality dietary additives in Europe due to a rising geriatric population and increasing awareness towards the potential benefits of probiotics strain-induced diets.
  • Changing perceptions towards animal rights and increasing demand for high-quality animal derivative products, such as eggs, meat, and milk in Asia-Pacific is expected to open new avenues for probiotics industry expansion.
  • Some of the major players operating in the probiotics market include Arla Foods, BioGaia AB, DuPont Danisco, Danone, I- Health, Nestle, and Nebraska Cultures
  • Companies are investing in R&D to develop hybrid varieties of strains to counter side effects and diversify product portfolio, which is likely to foster industry growth

Supportive government regulations in Europe and North America towards the use of probiotic strains in the food and beverage market and in animal feed may boost market share. Manufacturers are expanding product portfolios and diversifying segments by introducing probiotics enhanced alternatives, which may boost industry growth.

Browse key industry insights spread across 310 pages with 363 market data tables and 51 figures and charts from the report, “Probiotics Market Share By Ingredients (Lactobacilli, Bifidobacterium, Streptococcus, Bacillus), By End-Use (Human, Animal), By Application (Food and Beverages {Dairy Products, Non-Dairy Products, Cereals, Baked Food, Fermented Meat Products, Dry Food}, Dietary Supplements {Food, Nutritional, Specialty Nutrients, Infant Formula}, Animal Feed), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 -2026,” in detail along, with the table of contents: www.gminsights.com

Facility expansion is part of a $100M Investment to enhance the delivery of essential health innovations to consumers

DuPont announced the opening of a new state-of-the-art probiotics fermentation unit at its Rochester, New York (USA), facility. Construction of the unit was completed in March as part of an overall $100MM investment to expand probiotics capacity. The facility is now producing high-quality probiotics for the dietary supplement and food and beverage industries, which have the potential to provide health benefits to consumers of all ages.

The state-of-the-art facility incorporates several new production innovations, including:

  • The world’s largest fermenter for probiotics production and its downstream processing.
  • A built-in, fully automated system of sensors and monitors that helps maintain optimal growing conditions, removing the need to take traditional manual samples.
  • Pressurized air technology to mix fermenting solutions, replacing traditional pumps and mixing blades that can damage bacteria.
  • New bacteria freezing technology for safe storage of the probiotics that significantly increases efficiency.

DuPont develops and produces a wide range of clinically-documented probiotic strains for products sold globally. In the United States alone, more than 16 million U.S. households are purchasing probiotics, which deliver a variety of functional health benefits – from digestive and immune health to promising advancements in weight management and even cognitive health. Specifically, HOWARU® Shape – which is part of the DuPont Danisco® portfolio – most recently won “Ingredient of the Year for Weight Management” at the NutraIngredients Asia Awards.

The range, which now includes DuPont HOWARU® premium probiotics, is specially designed for fermented plant-based products, responding to key health, wellness and taste and texture trends

DuPont Nutrition & Biosciences (DuPont) announced a new cultures line that contains its premium HOWARU® probiotics which are specially designed for fermented plant-based products to deliver clinically backed health benefits. The DuPont Danisco® VEGE cultures range offers desired taste and texture profiles in non-dairy applications. New additions to this range – HOWARU® Dophilus VG, which contains Lactobacillus acidophilus NCFM® and HOWARU® Bifido VG, which contains Bifidobacterium lactis HN019 – have highly documented, positive results in human studies for digestive health and well-being.

Available in single strain form, this range is non-dairy, non-animal, non-allergen, non-GMO, and is suitable for vegan diets. It also is easy to integrate with existing cultures used in plant-based fermented food and beverage formulations.

“Digestive wellness is one of the top global trends for 2019. As consumers continue to make health and wellness part of their daily routines, they’re looking for benefit-focused options,” said Sonia Huppert, Global Product Leader, Plant-Based Products, DuPont. “Digestive health is an area where consumers can feel the benefits immediately. Symptoms like bloating and irregularity are treated with diet changes and with new products. Innovations in fermentation and probiotics can truly deliver solutions in this area.”

DuPont conducted a research study with Global Data Insights to ascertain consumer perception of probiotics. When asked the impact respondents believe that probiotics have on health and wellness, 46 percent of the nearly 12,000 respondents in Europe said probiotics had a positive effect, and 65 percent of respondents in the United States responded positively.

Validated by robust clinical trials, the HOWARU® brand is a high activity, premium probiotic product with high performance, high stability and high functionality as its hallmark traits.

These cultures not only respond to important wellness trends, but also to the increased demand for plant-based foods and the constant desire for great taste and texture. DuPont Danisco® VEGE cultures were developed for a wide-ranging variety of plant-based raw materials, such as soy, peas, coconut, almond, nuts, oat, maize, rice, fruits and vegetables, to satisfy consumer taste and texture expectations – from typical and appealing fresh, clean and mild flavors to new, pleasant unexpected flavors.

“We have the broadest portfolio for plant-based fermented foods and beverages and a deep passion to not only help deliver the food experience consumers desire, but also to bring the health benefits they’re continually seeking,” said Didier Carcano, Global Marketing Leader, Cultures, DuPont. “We aim to continue investing in this area, growing our probiotics expansion efforts and working with our customers to create essential health solutions for growth opportunities across the globe.”

World’s largest probiotics fermentation unit is operational at the DuPont Rochester facility 

DuPont announced it has completed construction on a new, state-of-the art probiotics fermentation unit at its Rochester, New York, facility. The unit, now largest in the world, is part of a multiphase nearly $100 million investment to expand probiotics capacity and enhance the company’s leadership in delivering high-quality, clinically documented probiotics to dietary supplement and food and beverage manufacturers.

The fermentation unit is fully operational and will serve as a crucial resource in propagating bacteria and enabling high potency, stability and efficacy of probiotics. Quality is extremely important in probiotic production, and the fermentation unit will also optimize DuPont’s production capability, enabling the company to increase the pace of delivery to customers and the market.

DuPont also completed a probiotics capacity expansion at its Madison, Wisconsin, facility in late 2018. The investment was used to upgrade equipment and increase the pace of new product development and significantly improved delivery times on pilot material for clinical trials and customer evaluations.

The healthy snacks made with real fruits and vegetables – strawberry, mango, kiwi, raspberry, spinach – contain a billion probiotics per 200 mL serving!

Like all iögo products, these marvellously creamy delights contain no gelatin, artificial colours, artificial flavours, preservatives or gluten.

The practical size and go-anywhere packaging make them the perfect day-starter for busy people.

Each 200 mL serving contains 15 % of the recommended daily intake of calcium and is also rich in vitamins B12 and B5, phosphorous and riboflavin.

Good news for the lactose intolerant: lactose-free versions are also available!

www.agropur.com